No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SON240816C50000
- 2.25
- -0.65-22.41%
15min DelayTrading Jul 22 10:12 ET
2.58High2.25Low
2.58Open2.90Pre Close5 Volume276 Open Interest50.00Strike Price1.16KTurnover23.28%IV1.34%PremiumAug 16, 2024Expiry Date1.56Intrinsic Value100Multiplier25DDays to Expiry0.69Extrinsic Value100Contract SizeAmericanOptions Type0.7105Delta0.1081Gamma22.66Leverage Ratio-0.0263Theta0.0240Rho16.10Eff Leverage0.0465Vega
Intraday
- 5D
- Daily
News
Sonoco Products Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution
In the last year, many Sonoco Products Company (NYSE:SON) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When evaluating insider transactions,
Breaking Down Sonoco Prods: 4 Analysts Share Their Views
In the latest quarter, 4 analysts provided ratings for Sonoco Prods (NYSE:SON), showcasing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the table below illustrates
Express News | Sonoco Products Co : Raymond James Initiates Coverage With Outperform Rating; Target Price $62
Express News | Raymond James Initiates Coverage On Sonoco Prods With Outperform Rating, Announces Price Target of $62
Raymond James Initiates Sonoco Products(SON.US) With Buy Rating, Announces Target Price $62
Raymond James analyst Matt Roberts initiates coverage on $Sonoco Products(SON.US)$ with a buy rating, and sets the target price at $62.According to TipRanks data, the analyst has a success rate of 100
Wells Fargo Maintains Sonoco Products(SON.US) With Hold Rating, Announces Target Price $55
Wells Fargo analyst Gabrial Hajde maintains $Sonoco Products(SON.US)$ with a hold rating, and sets the target price at $55.According to TipRanks data, the analyst has a success rate of 56.3% and a
Comments
Despite recent insider selling at Sonoco Products, shareholders need not worry deeply as insiders retain considerable company ownership, suggesting alignment with shareholders. Notably, the buying activity over the past year signals insider enthusiasm.
One Sonoco Products Insider Raised Stake By 99% In Previous YearSonoco's decent ROE comes with high debt levels, indicating risk. High ROEs without excessive debt denote good quality. Among companies with similar debt-to-equity ratios, a higher ROE is preferable.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $Oak Street Health(OSH.US$ -up 26.6%
2. $Baidu(BIDU.US$ -up 7.5%
3. $BP PLC(BP.US$ -up 3.2%
4. $Fiserv(FISV.US$ -up 2.4%
5. $Mitsubishi UFJ Financial Group(MUFG.US$ -up 1.4%
6. $GlaxoSmithKline(GSK.US$ -up 0.8%
7. $Microsoft(MSFT.US$ -up 0.7%
8. $Sanofi(SNY.US$ -up 0.5%
9. $Activision Blizzard(ATVI.US$ -up 0.4% ...
Gap Ups
1. $Oak Street Health(OSH.US$ -up 26.6%
2. $Baidu(BIDU.US$ -up 7.5%
3. $BP PLC(BP.US$ -up 3.2%
4. $Fiserv(FISV.US$ -up 2.4%
5. $Mitsubishi UFJ Financial Group(MUFG.US$ -up 1.4%
6. $GlaxoSmithKline(GSK.US$ -up 0.8%
7. $Microsoft(MSFT.US$ -up 0.7%
8. $Sanofi(SNY.US$ -up 0.5%
9. $Activision Blizzard(ATVI.US$ -up 0.4% ...
+15
8
Gapping up
In reaction to earnings/guidance:
• $New Relic(NEWR.US$ +3.8% (guidance), $American Airlines(AAL.US$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
In reaction to earnings/guidance:
• $New Relic(NEWR.US$ +3.8% (guidance), $American Airlines(AAL.US$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
6
Upgrades
• $Coupang(CPNG.US$ : Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $28)
• $First Republic Bank(FRC.US$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $188 (from $210)
• $Sitio Royalties(STR.US$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $43 (from $36)
Downgrades
• $Duck Creek Technologies(DCT.US$ : JMP Securities Downgrades to Market Perform from Market Outperform
•...
• $Coupang(CPNG.US$ : Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $28)
• $First Republic Bank(FRC.US$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $188 (from $210)
• $Sitio Royalties(STR.US$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $43 (from $36)
Downgrades
• $Duck Creek Technologies(DCT.US$ : JMP Securities Downgrades to Market Perform from Market Outperform
•...
14
Read more